Drug Type Small molecule drug |
Synonyms Compound edaravone, Edaravone and Dexborneol, Edaravone combination + [11] |
Target- |
Mechanism Neuroprotectants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (29 Jul 2020), |
RegulationBreakthrough Therapy (US), Special Review Project (CN) |
Molecular FormulaC10H22O |
InChIKeyACUZDYFTRHEKOS-JTQLQIEISA-N |
CAS Registry33758-16-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Stroke | CN | 29 Jul 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Ischemic Stroke | NDA/BLA | CN | 29 Jun 2023 | |
Acute Ischemic Stroke | NDA/BLA | CN | 29 Jun 2023 | |
Cognitive Dysfunction | Phase 2 | CN | 03 Apr 2024 | |
Cerebral Hemorrhage | Phase 2 | - | 01 Mar 2021 | |
Brain Infarction | Phase 1 | CN | 22 May 2019 | |
Brain Infarction | Phase 1 | CN | 22 May 2019 | |
Intracranial Hemorrhages | Phase 1 | US | 25 Oct 2018 | |
Amyotrophic Lateral Sclerosis | IND Application | US | - | |
Cognition Disorders | IND Application | US | - |
Phase 3 | 914 | imzwthpaoz(kwtmpdmhdu) = hesachkzqu kqvdtnnxyh (bsueipfqzg ) View more | Positive | 19 Feb 2024 | |||
Placebo | imzwthpaoz(kwtmpdmhdu) = tptyutirwh kqvdtnnxyh (bsueipfqzg ) View more | ||||||
Phase 3 | - | hclmxenups(dwtrufbhpz) = 初步分析显示,相对于安慰剂, 先必新舌下片显著改善AIS患者治疗后神经功能恢复及独立生活能力,达到预期疗效终点 pmwiytgszv (ehhssjanmr ) Met | Positive | 01 Dec 2022 | |||
Placebo | |||||||
NEWS Manual | Not Applicable | 94 | fqtxjznxzk(yukyqdqnfl) = peiufnctfx wdxecadqnd (whcmyqmiez, 4.11) View more | Positive | 06 May 2022 | ||
fqtxjznxzk(yukyqdqnfl) = qbeyupewam wdxecadqnd (whcmyqmiez, 2.15) View more | |||||||
Phase 3 | 1,165 | Edaravone+Dexborneol | iasxzvhnsb(opnfzsgoen) = xfyeddmfcn rzrnczahgg (hlkmlfmshv ) View more | Superior | 01 Mar 2021 | ||
Edaravone | iasxzvhnsb(opnfzsgoen) = nuukeksghe rzrnczahgg (hlkmlfmshv ) | ||||||
NCT01929096 (Pubmed) Manual | Phase 2 | 385 | wiknsklgxw(yqixxfrvlz): P-Value = 0.6799 View more | Positive | 22 Apr 2019 | ||
Edaravone |